Novartis Partners with Monte Rosa to Develop Immune Disease Treatment
New England Council member Novartis has partnered with a Boston- based biotech company Monte Rosa Therapeutics to develop a new immune disease treatment.
Last year, Novartis partnered with Monte Rosa on the development, manufacturing and commercializing of its drug, MRT-6160, a drug that could potentially provide therapeutic benefits in systemic and neurological autoimmune diseases like multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and dermatological disorder.
This recent partnership will also focus on the development of medicines for immune-mediated diseases. Monte Rosa develops molecular glue degrader-based medicines, which are small molecules that target and help destroy harmful proteins.
“We are pleased to expand our collaboration with Monte Rosa Therapeutics, building on the strong foundation and progress established through the VAV1 program,” Fiona Marshall, Ph.D., President of Biomedical Research at Novartis, said in the Sept. 15 release. “This new agreement underscores our commitment to advancing targeted protein degradation as a promising approach to address immune-mediated diseases with high unmet need,” Marshall added.
The New England Council commends Novartis for its its commitment to advancing vital pharmaceutical research and development.
Read more via the Boston Business Journal or Fierce Biotech